News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Press Releases

Epigenomics AG places maximum number of mandatory convertible bonds with a total volume of EUR 16.5 million

DGAP-News: Epigenomics AG / Key word(s): Bond/Issue of Debt13.09.2021 / 13:24 The issuer is solely responsible for the content of this announcement. NOT TO BE PUBLISHED, DISSEMINATED OR PASSED ON TO OR WITHIN THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA AND SOUTH AFRICA Press Release Epigenomics AG places maximum number of mandatory convertible bonds […]

Read more

​​​​​​​New study in the BMC Cancer journal shows that Epi proColon(R) is an effective method to increase CRC screening rates in medically underserved populations

DGAP-News: Epigenomics AG / Key word(s): Study results/Study02.09.2021 / 13:42 The issuer is solely responsible for the content of this announcement. New study in the BMC Cancer journal shows that Epi proColon(R) is an effective method to increase CRC screening rates in medically underserved populations The availability of blood based mSEPT9 tests, such as Epi […]

Read more

Epigenomics AG: Securities prospectus for the issuance of a mandatory convertible bond in the amount of up to EUR 16.5 million approved by BaFin

DGAP-News: Epigenomics AG / Key word(s): Issue of Debt/Corporate Action24.08.2021 / 16:16 The issuer is solely responsible for the content of this announcement. NOT TO BE PUBLISHED, DISSEMINATED OR PASSED ON TO OR WITHIN THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA AND SOUTH AFRICA Press Release / Advertising Epigenomics AG: Securities prospectus for the […]

Read more

​​​​​​​Epigenomics AG Reports Financial Results for the First Six Months of 2021

DGAP-News: Epigenomics AG / Key word(s): Half Year Report/Half Year Results11.08.2021 / 08:00 The issuer is solely responsible for the content of this announcement. Epigenomics AG Reports Financial Results for the First Six Months of 2021 Berlin (Germany) and San Diego, CA (U.S.A.), August 11, 2021 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the “Company”) […]

Read more

Epigenomics AG Reports Financial Results for the First Quarter of 2021

DGAP-News: Epigenomics AG / Key word(s): Quarterly / Interim Statement/Quarter Results12.05.2021 / 08:00 The issuer is solely responsible for the content of this announcement. Press release Epigenomics AG Reports Financial Results for the First Quarter of 2021 Berlin (Germany) and San Diego, CA (U.S.A.), May 12, 2021 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the […]

Read more

Epigenomics AG decides to increase share capital through rights issue with subscription rights of existing shareholders

DGAP-News: Epigenomics AG / Key word(s): Capital Increase27.04.2021 / 17:40 The issuer is solely responsible for the content of this announcement. NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA AND SOUTH AFRICA. Press release Epigenomics AG decides to increase share capital through rights […]

Read more